CN110384679A - Cabazitaxel albumin nano granular preparation and the preparation method and application thereof - Google Patents
Cabazitaxel albumin nano granular preparation and the preparation method and application thereof Download PDFInfo
- Publication number
- CN110384679A CN110384679A CN201810338298.5A CN201810338298A CN110384679A CN 110384679 A CN110384679 A CN 110384679A CN 201810338298 A CN201810338298 A CN 201810338298A CN 110384679 A CN110384679 A CN 110384679A
- Authority
- CN
- China
- Prior art keywords
- cabazitaxel
- albumin
- nano granular
- preparation
- albumin nano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 title claims abstract 19
- 229960001573 cabazitaxel Drugs 0.000 title claims abstract 19
- 238000002360 preparation method Methods 0.000 title claims abstract 18
- 102000009027 Albumins Human genes 0.000 title claims abstract 16
- 108010088751 Albumins Proteins 0.000 title claims abstract 16
- 239000003960 organic solvent Substances 0.000 claims abstract 6
- 239000004094 surface-active agent Substances 0.000 claims abstract 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims abstract 5
- 239000012024 dehydrating agents Substances 0.000 claims abstract 4
- 239000002105 nanoparticle Substances 0.000 claims abstract 4
- 239000002994 raw material Substances 0.000 claims abstract 4
- 239000003381 stabilizer Substances 0.000 claims abstract 4
- 239000003795 chemical substances by application Substances 0.000 claims 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 238000003756 stirring Methods 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 238000004132 cross linking Methods 0.000 claims 2
- 230000018044 dehydration Effects 0.000 claims 2
- 238000006297 dehydration reaction Methods 0.000 claims 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 235000019441 ethanol Nutrition 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- -1 polyethylene Polymers 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 239000004626 polylactic acid Substances 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229920000136 polysorbate Polymers 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of Cabazitaxel albumin nano granular preparations, are prepared by the raw material of following proportion: Cabazitaxel 3-185mg, albumin 10-650mg, glutaraldehyde 1-50ul, dehydrating agent 0.5-25g, organic solvent 1-10ml, stabilizer 0-800ul, surfactant 0-800ul.Above-mentioned nano particle preparations have excellent targeting, can rapid dispersion and diseased region accumulate, improve diseased region Cabazitaxel concentration, improve curative effect of medication.In use, without being diluted to drug, moreover it is possible to avoid the adverse reactions such as -80 bring allergy of surface active agent tween.
Description
Technical field
The present invention relates to pharmaceutical technology fields, more particularly to Cabazitaxel albumin nano granular preparation and preparation method thereof
With application.
Background technique
Cabazitaxel (cabazitaxel) is broad-spectrum anti-cancer drug, is one of the member of Japanese yew alkanamine family, belongs to anti-
Micro-pipe class drug, it is main by reinforcing tubulin polymerization and inhibiting microtubule depolymerization to form stable non-functional micro-pipe
Beam has the function of to inhibit mitosis and intermitotic tumour cell, plays antitumor action.Cabazitaxel can be with prednisone
Or prednisolone combination, for treating the transfer sex hormone difficulty control type prostate cancer trouble for having received docetaxel therapy before this
Person.
By French Sanofi-Aventis (Sanofi-Aventis) company exploitation Cabazitaxel injection June 17 in 2010
Number by FDA ratify list, trade name Jevtana.But Cabazitaxel water solubility is poor, which must dissolve drug
In Tween-80, be diluted to 10mg/ml with 13% ethyl alcohol again using preceding, before drug administration by injection further with 5% glucose or
Person's normal saline dilution is to clinical use concentration.Use process time and effort consuming.Also, when clinical use, Cabazitaxel itself
Taxane structure and microtubulin-resisting activity, make its be easy to appear in Tween formulation serious allergic reaction, body fluid storage stay with
And the adverse reaction of Organic selection difference etc., inconvenience and safety issue are brought to clinical application.
Summary of the invention
Based on this, it is necessary in view of the above-mentioned problems, providing a kind of Cabazitaxel albumin nano granular preparation and its preparation side
Method.
The present invention provides a kind of Cabazitaxel albumin nano granular preparation.
The specific technical proposal is:
A kind of Cabazitaxel albumin nano granular preparation, is prepared by the raw material of following proportion:
Cabazitaxel 3-185mg, albumin 10-650mg, glutaraldehyde 1-50ul, dehydrating agent 0.5-25g, organic solvent 1-
10ml, stabilizer 0-800ul, surfactant 0-800ul.
In one of the embodiments, the Cabazitaxel albumin nano granular preparation by following proportion raw material preparation and
At:
Cabazitaxel 5-50mg, albumin 12.5-200mg, glutaraldehyde 1-25ul, dehydrating agent 3-20g, organic solvent 3-
5ml, stabilizer 0-500ul, surfactant 0-500ul.
In one of the embodiments, the Cabazitaxel albumin nano granular preparation by following proportion raw material preparation and
At:
It is Cabazitaxel 10-15mg, albumin 25-50mg, glutaraldehyde 1-10ul, dehydrating agent 3-10g, organic solvent 4ml, steady
Determine agent 0-100ul, surfactant 0-100ul.
The dehydrating agent is selected from methanol, ethyl alcohol or acetone in one of the embodiments,.
The organic solvent is selected from methylene chloride in one of the embodiments,.
The surfactant is selected from poloxamer in one of the embodiments,.
The stabilizer is selected from polyethylene glycol-polylactic acid in one of the embodiments,.
The present invention also provides the preparation methods of above-mentioned Cabazitaxel albumin nano granular preparation, comprising the following steps:
The Cabazitaxel, albumin and surfactant are added in the organic solvent, adjusts pH to 6-11, is added
Dehydrating agent stirring adds glutaraldehyde and stabilizer until forming nanoparticle, stirring crosslinking to get.
The time of the stirring crosslinking is 12-24h in one of the embodiments,.
The present invention also provides a kind of above-mentioned Cabazitaxel albumin nano granular preparations in preparation treatment anti-tumor drug
Using.
Compared with prior art, the invention has the following advantages:
Above-mentioned Cabazitaxel preparation is packed in nanoscale particle using albumin nano granular as pharmaceutical carrier, by Cabazitaxel
In, and crosslinking agent is added into nanoparticle, makes nanoparticle crosslinking curing, Cabazitaxel can be sustained and extend it in vivo
Half-life period, meanwhile, albumin targets material can be by the Cabazitaxel Targeting delivery in nanoparticle, after administration, above-mentioned nanometer
Grain granulation have excellent targeting, can rapid dispersion and diseased region accumulate, improve diseased region Cabazitaxel it is dense
Degree improves curative effect of medication.In use, without repeatedly being diluted to drug, moreover it is possible to avoid -80 bring of surface active agent tween
The adverse reactions such as allergy.
Surfactant and stabilizer are added into Cabazitaxel preparation, the encapsulation rate and carrying drug ratio of nanoparticle can be improved.
Further, above-mentioned preparation method coats absorption method using desolvation and physics, has fast and convenient, cost
The features such as low, strong operability, relatively narrow particle diameter distribution.The partial size of obtained Cabazitaxel preparation is 50-250nm, average grain diameter
For 185nm.
Specific embodiment
Below in conjunction with specific embodiment to Cabazitaxel albumin nano granular preparation of the invention and preparation method thereof with answer
With being described in further detail.
Embodiment 1
Precision weighs 12.5mg Cabazitaxel and 25mg albumin, is dissolved in 4ml methylene chloride, and adjusting pH value is 8, room
The lower stirring of temperature, being continuously added into 10ml ethyl alcohol with the rate of 0.5mI/min, (quality 7.89g, 20 DEG C of density are 0.789g/
cm3), until forming Cabazitaxel albumin nano granular, add 8% glutaraldehyde water solution of 29ul and be allowed to be crosslinked, when crosslinking holds
Continuous stirring 12-24h, is obtained nanoparticle colloidal suspension, its low-grade fever is stayed overnight, removed volatile substances, freezed using conventional method
It is drying to obtain.
The partial size that above-mentioned Cabazitaxel albumin preparation is detected with laser light scattering instrument is 189nm, and particle diameter distribution is
90.6%.
For electric nanoparticle form visible under the microscope compared with rounding, particle diameter distribution is relatively narrow.
Using supercentrifugal process, measuring entrapment efficiency is 95%.
Embodiment 2
Precision weighs 12.5mg Cabazitaxel and 50mg albumin, is dissolved in 4ml methylene chloride, and adjusting pH value is 8, room
The lower stirring of temperature, being continuously added into 12ml ethyl alcohol with the rate of 0.5mI/min, (quality 9.468g, 20 DEG C of density are 0.789g/
cm3), until forming Cabazitaxel albumin nano granular, add 8% glutaraldehyde water solution of 27ul and be allowed to be crosslinked, when crosslinking holds
Continuous stirring 12-24h, is obtained nanoparticle colloidal suspension, its low-grade fever is stayed overnight, removed volatile substances, freezed using conventional method
It is drying to obtain.
It is 191.4nm, particle diameter distribution 88.6% with the partial size that laser light scattering instrument detects above-mentioned Cabazitaxel preparation.
For electric nanoparticle form visible under the microscope compared with rounding, particle diameter distribution is relatively narrow.
Using supercentrifugal process, measuring entrapment efficiency is 93%.
Embodiment 3
Precision weighs 50mg Cabazitaxel, 100mg albumin and 5ul poloxamer, is dissolved in 5ml methylene chloride, adjusts
Saving pH value is 8, stirs at room temperature, is continuously added into the 20ml ethyl alcohol (density that 15.78,20 DEG C of quality with the rate of 0.5mI/min
For 0.789g/cm3), until forming Cabazitaxel albumin nano granular, adds 8% glutaraldehyde water solution of 30ml and 10ul is poly-
Ethylene glycol-polylactic acid, when crosslinking, persistently stir 12-24h, obtain nanoparticle colloidal suspension, its low-grade fever is stayed overnight, and remove volatile
Substance is freeze-dried using conventional method to obtain the final product.
It is 198nm, particle diameter distribution 85.1% with the partial size that laser light scattering instrument detects above-mentioned Cabazitaxel preparation.
For electric nanoparticle form visible under the microscope compared with rounding, particle diameter distribution is relatively narrow.
Using supercentrifugal process, measuring entrapment efficiency is 96%.
The Cabazitaxel preparation more rounding of embodiment 1-3, narrower particle size distribution, partial size model circle is 60-280nm, average
Partial size is about 193nm.It can be made freeze-dried with dry bath method is freezed, before use, aquation is redissolved, obtain injection, direct injection is given
Medicine.
Effect test
BALB/c mouse is taken, is divided into five groups of A-E, every group 10, inoculates 107A mouse mastopathy cell EMT-6, connects
After kind tumour for 24 hours, the Cabazitaxel preparation of embodiment 1-3 is injected respectively in A-C group mouse peritoneal, once a day, continuous 5 days, D
Group injects isometric sterile saline, and E group injects isometric Cabazitaxel.It is living after groups of animals inoculated tumour 12 days
It kills, weighs after going tumour, calculate each group drug to the inhibiting rate of tumour, the results are shown in Table 1.
Inhibiting rate %=(control group tumor weight-treatment group tumors weight)/control group tumor weight * 100%
Table 1
| Dosage (mg/kg) | Knurl weight (g) | Inhibiting rate | |
| A (embodiment 1) | 5 | 0.25 | 82% |
| B (embodiment 2) | 5 | 0.46 | 67% |
| C (embodiment 3) | 4 | 0.54 | 61% |
| D (control group) | 5 | 1.41 | 0 |
| E (only injection Cabazitaxel) | 5 | 0.84 | 40% |
Each technical characteristic of embodiment described above can be combined arbitrarily, for simplicity of description, not to above-mentioned reality
It applies all possible combination of each technical characteristic in example to be all described, as long as however, the combination of these technical characteristics is not deposited
In contradiction, all should be considered as described in this specification.
The embodiments described above only express several embodiments of the present invention, and the description thereof is more specific and detailed, but simultaneously
Limitations on the scope of the patent of the present invention therefore cannot be interpreted as.It should be pointed out that for those of ordinary skill in the art
For, without departing from the inventive concept of the premise, various modifications and improvements can be made, these belong to guarantor of the invention
Protect range.Therefore, the scope of protection of the patent of the invention shall be subject to the appended claims.
Claims (10)
1. a kind of Cabazitaxel albumin nano granular preparation, which is characterized in that be prepared by the raw material of following proportion:
Cabazitaxel 3-185mg, albumin 10-650mg, glutaraldehyde 1-50ul, dehydrating agent 0.5-25g, organic solvent 1-10ml,
Stabilizer 0-800ul, surfactant 0-800ul.
2. Cabazitaxel albumin nano granular preparation according to claim 1, which is characterized in that the white egg of Cabazitaxel
White nano particle preparations are prepared by the raw material of following proportion:
It is Cabazitaxel 5-50mg, albumin 12.5-200mg, glutaraldehyde 1-25ul, dehydrating agent 3-20g, organic solvent 3-5ml, steady
Determine agent 0-500ul, surfactant 0-500ul.
3. Cabazitaxel albumin nano granular preparation according to claim 2, which is characterized in that the white egg of Cabazitaxel
White nano particle preparations are prepared by the raw material of following proportion:
Cabazitaxel 10-15mg, albumin 25-50mg, glutaraldehyde 1-10ul, dehydrating agent 3-10g, organic solvent 4ml, stabilizer
0-100ul, surfactant 0-100ul.
4. Cabazitaxel albumin nano granular preparation according to claim 1-3, which is characterized in that the dehydration
Agent is selected from methanol, ethyl alcohol or acetone.
5. Cabazitaxel albumin nano granular preparation according to claim 1-3, which is characterized in that described organic
Solvent is selected from methylene chloride.
6. Cabazitaxel albumin nano granular preparation according to claim 1-3, which is characterized in that the surface
Activating agent is selected from poloxamer.
7. Cabazitaxel albumin nano granular preparation according to claim 1-3, which is characterized in that the stabilization
Agent is selected from polyethylene glycol-polylactic acid.
8. a kind of preparation method of the described in any item Cabazitaxel albumin nano granular preparations of claim 1-7, feature exist
In, comprising the following steps:
The Cabazitaxel, albumin and surfactant are added in the organic solvent, adjusts pH to 6-11, dehydration is added
Agent stirring adds glutaraldehyde and stabilizer until forming nanoparticle, stirring crosslinking to get.
9. preparation method according to claim 8, which is characterized in that the time of the stirring crosslinking is 12-24h.
10. a kind of described in any item Cabazitaxel albumin nano granular preparations of claim 1-7 treat antineoplastic in preparation
Application in object.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810338298.5A CN110384679A (en) | 2018-04-16 | 2018-04-16 | Cabazitaxel albumin nano granular preparation and the preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810338298.5A CN110384679A (en) | 2018-04-16 | 2018-04-16 | Cabazitaxel albumin nano granular preparation and the preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110384679A true CN110384679A (en) | 2019-10-29 |
Family
ID=68282925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810338298.5A Pending CN110384679A (en) | 2018-04-16 | 2018-04-16 | Cabazitaxel albumin nano granular preparation and the preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110384679A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1616089A (en) * | 2004-09-17 | 2005-05-18 | 中国人民解放军第二军医大学 | Sodium ferulate albumin nanoparticle preparation and preparation method thereof |
| US20140056996A1 (en) * | 2011-02-25 | 2014-02-27 | Aventis Pharma S.A. | Antitumoral combination comprising cabazitaxel and cisplatin |
| CN104490797A (en) * | 2014-12-22 | 2015-04-08 | 深圳海王药业有限公司 | Multiphase-stable albumin conjunction type cabazitaxel |
| CN105078904A (en) * | 2015-06-25 | 2015-11-25 | 南京优科生物医药有限公司 | Cabazitaxel lipid microsphere albumin freeze-dried powder injection and preparation method thereof |
| CN106580880A (en) * | 2016-12-22 | 2017-04-26 | 深圳海王医药科技研究院有限公司 | Stable cabazitaxel particle redispersible system |
-
2018
- 2018-04-16 CN CN201810338298.5A patent/CN110384679A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1616089A (en) * | 2004-09-17 | 2005-05-18 | 中国人民解放军第二军医大学 | Sodium ferulate albumin nanoparticle preparation and preparation method thereof |
| US20140056996A1 (en) * | 2011-02-25 | 2014-02-27 | Aventis Pharma S.A. | Antitumoral combination comprising cabazitaxel and cisplatin |
| CN104490797A (en) * | 2014-12-22 | 2015-04-08 | 深圳海王药业有限公司 | Multiphase-stable albumin conjunction type cabazitaxel |
| CN105078904A (en) * | 2015-06-25 | 2015-11-25 | 南京优科生物医药有限公司 | Cabazitaxel lipid microsphere albumin freeze-dried powder injection and preparation method thereof |
| CN106580880A (en) * | 2016-12-22 | 2017-04-26 | 深圳海王医药科技研究院有限公司 | Stable cabazitaxel particle redispersible system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhao et al. | Long-term storage of lipid-like nanoparticles for mRNA delivery | |
| Wei et al. | Thermo-sensitive polypeptide hydrogel for locally sequential delivery of two-pronged antitumor drugs | |
| Qu et al. | Docetaxel-loaded human serum albumin (HSA) nanoparticles: synthesis, characterization, and evaluation | |
| Soni et al. | Nanogels as potential nanomedicine carrier for treatment of cancer: A mini review of the state of the art | |
| Chen et al. | Biodegradable PEG-poly (ω-pentadecalactone-co-p-dioxanone) nanoparticles for enhanced and sustained drug delivery to treat brain tumors | |
| Ebrahimian et al. | Co-delivery of doxorubicin encapsulated PLGA nanoparticles and Bcl-xL shRNA using alkyl-modified PEI into breast cancer cells | |
| Khan et al. | Biodegradable nano-architectural PEGylated approach for the improved stability and anticancer efficacy of bendamustine | |
| Pradhan et al. | Hyaluronic acid-decorated poly (lactic-co-glycolic acid) nanoparticles for combined delivery of docetaxel and tanespimycin | |
| CN106137969B (en) | Docetaxel albumin nanoparticle pharmaceutical composition, preparation method and application thereof | |
| CN112933052A (en) | Nano drug delivery system for improving tumor hypoxia microenvironment and enhancing immunotherapy | |
| Daman et al. | Polymeric micelles of PEG-PLA copolymer as a carrier for salinomycin against gemcitabine-resistant pancreatic cancer | |
| CN103596558A (en) | Nanocapsules with a polymer shell | |
| EP1835888B1 (en) | Cholanic acid-chitosan complex forming self-aggregates and preparation method thereof | |
| Kang et al. | A negatively charged Pt (IV) prodrug for electrostatic complexation with polymers to overcome cisplatin resistance | |
| Firouzi-Amandi et al. | Development, characterization, and in vitro evaluation of cytotoxic activity of Rutin loaded PCL-PEG nanoparticles against Skov3 ovarian cancer cell | |
| WO2019007019A1 (en) | Psoralen polymernanoparticle preparation and preparation method therefor | |
| CN101843582B (en) | taxol nano suspension and preparation method thereof | |
| Jalilian et al. | Targeting solid lipid nanoparticles with anisamide for docetaxel delivery to prostate cancer: preparation, optimization, and in-vitro evaluation | |
| Türkeş et al. | Folic acid-conjugated cancer drug curcumin-loaded albumin nanoparticles: Investigation of curcumin release kinetics | |
| Yousefnezhad et al. | PCL-based nanoparticles for doxorubicin-ezetimibe co-delivery: A combination therapy for prostate cancer using a drug repurposing strategy | |
| Sun et al. | Engineering thio-/seleno-ether linkers into zwitterionic small molecule nano-prodrugs for traceable cancer theranostics | |
| Hu et al. | Enhanced antitumor efficacy of folate targeted nanoparticles co-loaded with docetaxel and curcumin | |
| Pandian et al. | Delivery of ursolic acid by polyhydroxybutyrate nanoparticles for cancer therapy: in silico and in vitro studies | |
| CN106983719A (en) | A kind of docetaxel polymer nano micelle injection, its preparation method and its application in tumor is prepared | |
| Dumbuya et al. | Exploring Disulfiram’s Anticancer Potential: PLGA Nano-Carriers for Prolonged Drug Delivery and Potential Improved Therapeutic Efficacy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200915 Address after: 510000 East Station Road, Tianhe District, Guangzhou City, Guangdong Province, Building R279, Area A, 3rd floor, East Station Complex Building, No. 1 East Station Road, Tianhe District, Guangzhou City Applicant after: GUANGZHOU KAIMO BIOTECHNOLOGY Co.,Ltd. Address before: 510000 3322, No. 382, Binjiang Middle Road, Haizhu District, Guangzhou City, Guangdong Province Applicant before: Guangzhou kaibaorui Pharmaceutical Technology Co.,Ltd. |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191029 |